Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E 21 versus JENCYCLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E 21 versus JENCYCLA.
ENOVID-E 21 vs JENCYCLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation; mestranol is an estrogen that stabilizes endometrium and provides cycle control.
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
One tablet (norethynodrel 2.5 mg, mestranol 0.1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication. Repeat cycle.
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
None Documented
None Documented
Terminal elimination half-life: 27–36 hours (mean 30.8 h). Steady-state reached after 5–7 days. Clinical context: allows once-daily dosing with stable estrogenic effect.
8-12 hours; prolonged to 24 hours in severe hepatic impairment
73% renal (45% as unchanged norethindrone, 20% as conjugates, 8% as other metabolites), 27% fecal via bile. Enterohepatic recirculation accounts for 15% of total clearance.
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive